Alexandra C Braun1, Marcus Gutmann1, Regina Ebert2, Franz Jakob2, Henning Gieseler3, Tessa Lühmann1, Lorenz Meinel4. 1. Institute for Pharmacy and Food Chemistry, University of Würzburg, Am Hubland, DE-97074, Würzburg, Germany. 2. Orthopedic Center for Musculoskeletal Research, University of Würzburg, Friedrich-Bergius-Ring 15, 97076, Würzburg, Germany. 3. GILYOS GmbH, Friedrich-Bergius-Ring 15, 97076, Würzburg, Germany. 4. Institute for Pharmacy and Food Chemistry, University of Würzburg, Am Hubland, DE-97074, Würzburg, Germany. lorenz.meinel@uni-wuerzburg.de.
Abstract
PURPOSE: The inhibition of myostatin - a member of the transforming growth factor (TGF-β) family - drives regeneration of functional skeletal muscle tissue. We developed a bioresponsive drug delivery system (DDS) linking release of a myostatin inhibitor (MI) to inflammatory flares of myositis to provide self-regulated MI concentration gradients within tissues of need. METHODS: A protease cleavable linker (PCL) - responding to MMP upregulation - is attached to the MI and site-specifically immobilized on microparticle surfaces. RESULTS: The PCL disintegrated in a matrix metalloproteinase (MMP) 1, 8, and particularly MMP-9 concentration dependent manner, with MMP-9 being an effective surrogate biomarker correlating with the activity of myositis. The bioactivity of particle-surface bound as well as released MI was confirmed by luciferase suppression in stably transfected HEK293 cells responding to myostatin induced SMAD phosphorylation. CONCLUSIONS: We developed a MMP-responsive DDS for MI delivery responding to inflammatory flare of a diseased muscle matching the kinetics of MMP-9 upregulation, with MMP-9 kinetics matching (patho-) physiological myostatin levels. ᅟ: Graphical Abstract Schematic illustration of the matrix metalloproteinase responsive delivery system responding to inflammatory flares of muscle disease. The protease cleavable linker readily disintegrates upon entry into the diseased tissue, therby releasing the mystatin inhibitor.
PURPOSE: The inhibition of myostatin - a member of the transforming growth factor (TGF-β) family - drives regeneration of functional skeletal muscle tissue. We developed a bioresponsive drug delivery system (DDS) linking release of a myostatin inhibitor (MI) to inflammatory flares of myositis to provide self-regulated MI concentration gradients within tissues of need. METHODS: A protease cleavable linker (PCL) - responding to MMP upregulation - is attached to the MI and site-specifically immobilized on microparticle surfaces. RESULTS: The PCL disintegrated in a matrix metalloproteinase (MMP) 1, 8, and particularly MMP-9 concentration dependent manner, with MMP-9 being an effective surrogate biomarker correlating with the activity of myositis. The bioactivity of particle-surface bound as well as released MI was confirmed by luciferase suppression in stably transfected HEK293 cells responding to myostatin induced SMAD phosphorylation. CONCLUSIONS: We developed a MMP-responsive DDS for MI delivery responding to inflammatory flare of a diseased muscle matching the kinetics of MMP-9 upregulation, with MMP-9 kinetics matching (patho-) physiological myostatin levels. ᅟ: Graphical Abstract Schematic illustration of the matrix metalloproteinase responsive delivery system responding to inflammatory flares of muscle disease. The protease cleavable linker readily disintegrates upon entry into the diseased tissue, therby releasing the mystatin inhibitor.
Authors: Takuo Yamaki; Chia-Ling Wu; Michael Gustin; Jamie Lim; Robert W Jackman; Susan C Kandarian Journal: Am J Physiol Cell Physiol Date: 2012-05-16 Impact factor: 4.249
Authors: Philipp S Lienemann; Maria Karlsson; Ana Sala; Hanna M Wischhusen; Franz E Weber; Roland Zimmermann; Wilfried Weber; Matthias P Lutolf; Martin Ehrbar Journal: Adv Healthc Mater Date: 2012-11-07 Impact factor: 9.933
Authors: Regina Ebert; Marlena Jovanovic; Matthias Ulmer; Doris Schneider; Jutta Meissner-Weigl; Jerzy Adamski; Franz Jakob Journal: Mol Endocrinol Date: 2004-07-08
Authors: J Ritzer; T Lühmann; C Rode; M Pein-Hackelbusch; I Immohr; U Schedler; T Thiele; S Stübinger; B V Rechenberg; J Waser-Althaus; F Schlottig; M Merli; H Dawe; M Karpíšek; R Wyrwa; M Schnabelrauch; L Meinel Journal: Nat Commun Date: 2017-08-15 Impact factor: 14.919
Authors: F Andrea Sass; Michael Fuchs; Matthias Pumberger; Sven Geissler; Georg N Duda; Carsten Perka; Katharina Schmidt-Bleek Journal: Int J Mol Sci Date: 2018-03-13 Impact factor: 5.923